Although ruxolitinib and erlotinib are not currently approved by FDA for breast cancer treatment, they are under investigation in multiple clinical trials for this purpose, and were included in the study since no drug targeting JAK2 or EGFR specifically (lapatinib inhibits both EGFR and HER2) is included in the FDA-approved list for breast cancer treatment at this time. The gene discussed is JAK2; the disease is breast carcinoma.